Andy Beck was rising up the ranks of the Harvard Medical School faculty when he quit to cofound PathAI with Aditya Khosla. Beck, who spent more than five years as a pathologist at Harvard, wants to make it easier for other pathologists to diagnose diseases like cancer by using machine learning to more quickly and accurately analyze images of cells. For the time being, its tools are used not so much by doctors as they are by researchers at pharmaceutical companies. The Boston-based startup boasts a client list of the world’s largest pharma giants, such as Novartis, Gilead Sciences and Bristol-Myers Squibb.
PathAI
Unlock to Claim this listing
Add / Modify Company
Click to rate this company
[Total: 0 Average: 0]
Click here to sign in to vote
2.85
Overall Excellence Rating
Industry
Information TechnologyCategory
Software DevelopmentESG/Ethical Impact
Our mission at PathAI is to improve patient outcomes with AI-powered pathology through: More Accurate Diagnosis. Matching Patients with the Most Effective Treatments. More Life-Saving Drug Approvals. Leadership Team: Our leadership team combines industry-leading expertise across diverse fields – engineering, machine learning, life sciences, medicine, regulatory, strategy, and operations – to help drive the PathAI mission forward with everyone in our organization.
Claim Your Award Badges
Do you work with Us
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.
Awards Received
2023
Revenues
81600000.00
Website Traffic
Employee Rating
3.10
Customer Rating
4.60
Company Size
100-1000
ESG Risk Rating
3.00
We’re Happy to Help.
Do you have questions about your ranking, our projects, or why you’re not on the list?